Search Result

Results for "

tumor suppressor kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (1) Ras (1) Wee1 (4) YAP (1)
By Research Areas:	Cancer (7)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Antibodies

Targets Recommended: HRASLS TNF Receptor BRK VISTA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128590

PHT-7.3 1 Publications Verification	Ras	Cancer
PHT-7.3 is a selective inhibitor of *connector enhancer of kinase* suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (K_d*=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor* growth and signaling. PHT-7.3 has antitumor activity .

HY-147082

GA-017 3 Publications Verification	YAP	Cancer
GA-017 is a potent and selective LATS1 and LATS2 (large tumor suppressor kinase 1/2) inhibitor, with IC₅₀ values of 4.10 and 3.92 nM, respectively. GA-017 is an activator of cell proliferation. GA-017 promotes YAP/TAZ activation and nuclear translocation. GA-017 promotes cell growth under 3D culture conditions. GA-017 enhances the ex vivo formation of mouse intestinal organoids .

HY-144999

LEB-03-146	Wee1	Cancer
LEB-03-146 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a PEG2 linker. LEB-03-146 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells .

HY-143342

LEB-03-144	Wee1	Cancer
LEB-03-144 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C3 alkyl linker. LEB-03-144 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells .

HY-143340

LEB-03-145	Wee1	Cancer
LEB-03-145 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C5 alkyl linker .

HY-143343

LEB-03-153	Wee1	Cancer
LEB-03-153 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through no linker .

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library	868 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 868 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

PI3K/Akt/mTOR Compound Library

868 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 868 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

Cat. No.	Compare	Product Name	Species	Source

HY-P704000

	LATS1 Protein, Human (His, Myc) Large tumor suppressor homolog 1; WARTS protein kinase (h-warts); WARTS	Human	E. coli
	LATS1 Protein, Human (His, Myc) is the recombinant human-derived LATS1 protein, expressed by E. coli, with C-Myc & N-10*His tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P86304

	LATS1 Antibody (YA5996) Serine/threonine-protein kinase LATS1; Large tumor suppressor homolog 1; WARTS protein kinase; h-warts;	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	LATS1 Antibody (YA5996) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LATS1.

HY-P86438

	CDKN2A/p16INK4a Antibody (YA6130) Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A; p16;	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	CDKN2A/p16INK4a Antibody (YA6130) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P81210

	phospho-LATS1+LATS2 (Thr1079 +Thr1041) Antibody LATS1 +LATS2 (phospho T1079 + T1041); Serine/threonine protein kinase LATS2; KPM; Large tumor supressor, homolog 1; LATS, large tumor suppressor, homolog 1 (Drosophila); LATS, large tumor suppressor, homolog 2 (Drosophila); LATS1 +LATS2 (phospho T1079 + T1041); p-LATS1 +LATS2(Thr1079 +Thr1041); RGD1564085; Serine/threonine protein kinase LATS1; WARTS; WARTS protein kinase; wts; 4932411G09Rik; AV277261; AW208599; AW228608; FLJ13161; LATS1_HUMAN.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse
	phospho-LATS1+LATS2 (Thr1079 +Thr1041) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to phospho-LATS1+LATS2 (Thr1079 +Thr1041).

HY-P80615

	CDKN2A/p16INK4a Antibody (YA508) 1 Publications Verification CDK4 inhibitor p16 INK4 antibody; CDK4I antibody; CDKN2 antibody; CDKN2A antibody; Cell cycle negative regulator beta antibody; CMM2 antibody; Cyclin dependent kinase 4 inhibitor A antibody; Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody; Cyclin Dependent kinase Inhibitor 2A antibody; Cyclin dependent kinase inhibitor 2A isoform 4 antibody; Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody; Cyclin dependent kinase inhibitor p16 antibody; INK4 antibody; INK4A antibody; MLM antibody; MTS1 antibody; Multiple tumor suppressor 1 antibody; p14 antibody; p16 antibody; P16INK4 antibody; p16INK4a antibody; p19 antibody; p19Arf antibody; TP16 antibody;	WB, IP	Human, Mouse
	CDKN2A/p16INK4a Antibody (YA508) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P80615A

	CDKN2A/p16INK4a Antibody (YA508)(PBS only) CDK4 inhibitor p16 INK4 antibody; CDK4I antibody; CDKN2 antibody; CDKN2A antibody; Cell cycle negative regulator beta antibody; CMM2 antibody; Cyclin dependent kinase 4 inhibitor A antibody; Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody; Cyclin Dependent kinase Inhibitor 2A antibody; Cyclin dependent kinase inhibitor 2A isoform 4 antibody; Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody; Cyclin dependent kinase inhibitor p16 antibody; INK4 antibody; INK4A antibody; MLM antibody; MTS1 antibody; Multiple tumor suppressor 1 antibody; p14 antibody; p16 antibody; P16INK4 antibody; p16INK4a antibody; p19 antibody; p19Arf antibody; TP16 antibody;	WB, IP	Human, Mouse
	CDKN2A/p16INK4a Antibody (YA508)(PBS only) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P85830

	CDKN2A/p16INK4a Antibody (YA5522) Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A; p16;	IHC-P, WB, ICC/IF, ELISA	Human
	CDKN2A/p16INK4a Antibody (YA5522) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CDKN2A/p16INK4a.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.